Vivani Medical (NASDAQ:VANI - Get Free Report) issued its earnings results on Monday. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01), Zacks reports.
Vivani Medical Price Performance
Shares of VANI traded down $0.05 during trading hours on Friday, hitting $0.94. The stock had a trading volume of 139,732 shares, compared to its average volume of 173,190. The stock has a market capitalization of $55.50 million, a price-to-earnings ratio of -2.08 and a beta of 3.20. The company's fifty day moving average is $1.12 and its two-hundred day moving average is $1.20. Vivani Medical has a 52 week low of $0.92 and a 52 week high of $2.22.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and issued a $4.00 target price on shares of Vivani Medical in a report on Friday.
Get Our Latest Research Report on VANI
Vivani Medical Company Profile
(
Get Free Report)
Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
Featured Stories
Before you consider Vivani Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vivani Medical wasn't on the list.
While Vivani Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
